Steroid News and Research

RSS

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Sports medicine physicians to convene at 2014 AMSSM Annual Meeting

More than 1,400 sports medicine physicians from the United States and abroad will attend the 23rd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM), the largest primary care sports medicine physician organization in the nation.

17 Mar 2014

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

"It's a whole new cancer world" and "I don't remember what it's like to have sleep" were the most common themes of mothers interviewed by University of Colorado Cancer Center researchers during the maintenance period after a child's treatment for acute lymphoblastic leukemia (ALL).

12 Mar 2014

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

10 Mar 2014

Study to understand how bisphenol-A may promote breast cancer growth

UT Arlington biochemists say their newly published study brings researchers a step closer to understanding how the commonly used synthetic compound bisphenol-A, or BPA, may promote breast cancer growth.

6 Mar 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Study demonstrates impact of vitamin D on social behavior linked with ASD

A new study by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute (CHORI) demonstrates the impact that Vitamin D may have on social behavior associated with Autism Spectrum Disorder (ASD).

26 Feb 2014

New way to potentially block chronic pain affecting osteoarthritis sufferers

Researchers from the Arthritis Research UK Pain Centre at The University of Nottingham have discovered a new way to potentially block the chronic and often debilitating pain affecting osteoarthritis sufferers.

26 Feb 2014

Medicines that mimic body's natural systems can prevent debilitating side effects

Debilitating side effects associated with prescription medication for some of today's most common conditions could be eradicated if they mimicked the body's natural hormone secretion cycles, a new report has said.

20 Feb 2014

Children exposed to cigarette smoke may have lesser response to asthma treatment

Children exposed to cigarette smoke at home have lower levels of an enzyme that helps them respond to asthma treatment, a study has found.

17 Feb 2014

Economy of bodily management responsible for widespread use of illegal steroids among MLB players

The widespread use of illegal steroids among Major League Baseball players has been fueled by an "economy of bodily management," the free agent market and exploding television revenues, a UT Arlington assistant professor argues in a newly published research paper.

16 Feb 2014

Researchers investigate sex differences in brain structure

Reviewing over 20 years of neuroscience research into sex differences in brain structure, a Cambridge University team has conducted the first meta-analysis of the evidence, published this week in the prestigious journal Neuroscience and Biobehavioral Reviews.

12 Feb 2014

Researchers demonstrate new approach to treating muscular dystrophy

Researchers at Washington University School of Medicine in St. Louis have demonstrated a new approach to treating muscular dystrophy. Mice with a form of this muscle-weakening disease showed improved strength and heart function when treated with nanoparticles loaded with rapamycin, an immunosuppressive drug recently found to improve recycling of cellular waste.

12 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Nestlé focuses on meeting world's increasing skin health needs

Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world's increasing skin health needs with a scientifically-proven broad range of innovative products.

11 Feb 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

RoundTable Healthcare Partners sells Aqua Pharmaceuticals Holdings for $402.6M to Almirall

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of Aqua Pharmaceuticals Holdings, Inc. to Almirall S.A. for up to $402.6 million in cash

16 Jan 2014

Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn’s disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. Patients and physicians often turn to this surgical intervention after a patient develops resistance to current treatments, such as steroids.

9 Jan 2014

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life.